Comparative Pharmacology
Head-to-head clinical analysis: GABITRIL versus VIGAFYDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABITRIL versus VIGAFYDE.
GABITRIL vs VIGAFYDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tiagabine inhibits gamma-aminobutyric acid (GABA) reuptake into presynaptic neurons, thereby increasing synaptic GABA levels and enhancing inhibitory neurotransmission.
Irreversible inhibitor of GABA transaminase, increasing brain GABA levels.
Initial dose: 4 mg orally twice daily. Titrate by 4-8 mg/day every 2 weeks. Maximum dose: 56 mg/day in 2-4 divided doses.
Adults: 50 mg/kg/day orally divided twice daily; maximum dose 3 g/day.
None Documented
None Documented
Terminal elimination half-life is 7–9 hours in healthy adults. In patients with hepatic impairment, half-life is prolonged (up to 12–24 hours) due to reduced clearance. No significant effect of renal impairment.
Terminal elimination half-life is 6-8 hours in adults; in neonates, it is prolonged to 16-20 hours due to immature renal function.
Approximately 70% of an oral dose is excreted in feces, 25% in urine, and 5% in bile. Renal elimination of unchanged drug is minimal (<2%); most is eliminated as metabolites.
Renal excretion of unchanged drug accounts for approximately 65-70% of elimination; biliary/fecal excretion is minimal (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant